Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATLAS study of inhaled pirfenidone (AP01) in idiopathic pulmonary fibrosis
NL-OMON50041Phase 2Completed
- Sponsor
- Avalyn Pharma, Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pirfenidone in idiopathic pulmonary fibrosis (IPF) (2 arms), sponsored by Avalyn Pharma, Inc. Primary endpoints: Treatment-emergent adverse events, Change from pre-dose to post-dose FEV1 after initial dose and 3 more. Started Aug 2019; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NL-OMON50041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50041.